Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 11/20 | 1.00 |
| ▸ | PRKACA | P17612 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKACG | P22612 | 4/20 | 1.00 |
| ▸ | PRKACB | P22694 | 4/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | PRKX | P51817 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372951 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL6969527 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL226317 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL30069136 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29378010 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| SCHEMBL29677841 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2456059 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL507871 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL2461354 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 | |
| Hydrochloric Acid SCHEMBL29781011 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKACAPRKCDPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090172-A1 | CELL CULTURE SYSTEMS COMPRISING MICROPATTERNED ARRAYS AND METHODS OF USE | ALTIS BIOSYSTEMS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4692329-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | The Asan Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4636079-A1 | METHOD FOR INDUCING DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND USE THEREOF | The Asan Foundation (KR) | 2025-10-22 | — | — | EP | claimed |
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | claimed |
| WO-2024210619-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | 재단법인 아산사회복지재단 | 2024-10-10 | — | — | WO | claimed |
| EP-4337675-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Universidad De Chile (CL) | 2024-03-20 | — | — | EP | claimed |
| EP-3372673-B1 | METHOD FOR PRODUCING CEREBELLAR PROGENITOR TISSUE | RIKEN (JP) | 2023-12-13 | — | — | EP | claimed |
| WO-2022238734-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2022-11-17 | — | — | WO | claimed |
| CN-106795487-B | Method for proliferating pancreatic progenitor cells | 武田药品工业株式会社 | 2021-11-19 | — | — | CN | claimed |
| EP-2839831-A1 | Modulators of the unconventional secretory pathway for use in the treatment of Alexander disease | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2015-02-25 | — | — | EP | claimed |
| EP-2377544-B1 | PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2014-10-22 | — | — | EP | claimed |
| WO-2014053709-A1 | A METHOD FOR CULTURING STEM CELLS | GLYKOS FINLAND OY (FI) | 2014-04-10 | — | — | WO | claimed |
| US-20130123345-A1 | METHOD OF TREATING A VIRAL INFECTION DYSFUNCTION BY DISRUPTING AN ADENOSINE RECEPTOR PATHWAY | THE OHIO STATE UNIVERSITY (US) | 2013-05-16 | — | — | US | claimed |
| US-20120172301-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANGIOTENSIN-(1-9), DERIVATIVES THEREOF, OR A VECTOR EXPRESSING ACE2, USEFUL FOR TREATING CARDIOVASCULAR, PULMONARY, CEREBRAL, AND/OR RENAL REMODELING | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2012-07-05 | — | — | US | claimed |
| EP-2377544-A2 | PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-(1-9) FOR CARDIOVASCULAR, PULMONARY AND/OR CEREBRAL TREATMENT | Pontificia Universidad Católica De Chile (CL) | 2011-10-19 | — | — | EP | claimed |
| US-20110130388-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | OSAKA UNIVERSITY (JP) | 2011-06-02 | — | — | US | claimed |
| EP-2319539-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | Osaka University (JP) | 2011-05-11 | — | — | EP | claimed |
| WO-2005120475-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BACTERIAL INFECTIONS AND SEPSIS | Technische Universität Dresden (DE) | 2005-12-22 | — | — | WO | claimed |
| EP-0885888-B1 | ISOQUINOLINE DERIVATIVES AND DRUGS | HIDAKA HIROYOSHI DR (JP) | 2003-08-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130388-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | RHOA, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885PRKACA 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.